Pleomorphic adenoma surgery: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:
==Indications==
==Indications==


*Surgical intervention is not recommended for the management of [disease name].
*Surgical intervention is recommended for the management of pleomorphic adenoma.
OR
*Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either:
**[Indication 1]
**[Indication 2]
**[Indication 3]
*The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either:
**[Indication 1]
**[Indication 2]
**[Indication 3]


==Surgery==
==Surgery==

Revision as of 14:57, 16 January 2019

Pleomorphic adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pleomorphic adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pleomorphic adenoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pleomorphic adenoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pleomorphic adenoma surgery

CDC on Pleomorphic adenoma surgery

Pleomorphic adenoma surgery in the news

Blogs on Pleomorphic adenoma surgery

Directions to Hospitals Treating Pleomorphic adenoma

Risk calculators and risk factors for Pleomorphic adenoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Indications

  • Surgical intervention is recommended for the management of pleomorphic adenoma.

Surgery

Surgery is the mainstay of treatment for pleomorphic adenoma.There are two procedures:

  • Superficial parotidectomy(Patey's operation).
  • Total parotidectomy, being the more frequently performed procedure due to lower incidence of recurrence. [1]
  • Meticulous care shouldbe taken to preserve the facial nerve. [1]
  • The tumors of the submandibular glands are treated with simple excision procedure with preservation of adjacent nerve including the mandibular branch of the trigeminal nerve, the hypoglossal nerve, and the lingual nerve.
  • When the tumor arises from the minor salivary glands, a five mm margin should be obtained.
  • Recurrence is also noticed after surgery.
  • The main causes for recurrence are:[2]
    • Incomplete excision
    • Intraoperative capsule rupture
    • Myxoid subtype
    • Presence of the satellite nodules and tumor extensions (pseudopodia)
    • Lack of the glandular tissue margin and the experience of the surgeon.

Contraindications

References

  1. 1.0 1.1 Kadletz, Lorenz; Grasl, Stefan; Grasl, Matthäus C.; Perisanidis, Christos; Erovic, Boban M. (2017). "Extracapsular dissection versus superficial parotidectomy in benign parotid gland tumors: The Vienna Medical School experience". Head & Neck. 39 (2): 356–360. doi:10.1002/hed.24598. ISSN 1043-3074.
  2. Kiciński K, Mikaszewski B, Stankiewicz C (February 2016). "Risk factors for recurrence of pleomorphic adenoma". Otolaryngol Pol. 70 (3): 1–7. doi:10.5604/00306657.1193691. PMID 27386926.

Template:WH Template:WS